List of Excipients in Branded Drug NYSTATIN TOPICAL POWDER

Generic Drugs Containing NYSTATIN TOPICAL POWDER

Company	Ingredient	NDC	Excipient
Epic Pharma LLC	nystatin topical powder	42806-178	TALC
Epic Pharma LLC	nystatin topical powder	42806-185	KAOLIN
Epic Pharma LLC	nystatin topical powder	42806-185	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NYSTATIN TOPICAL POWDER?

# Of NDCs	Excipient
1	KAOLIN
1	MAGNESIUM STEARATE
1	TALC

Nystatin Topical Powder Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

Nystatin topical powder is a mature prescription antifungal product with limited active-ingredient patent protection and a simple excipient profile. The main commercial opportunity is not new chemical-entity exclusivity. It is product differentiation through moisture control, low-dust delivery, improved skin tolerability, packaging, and distribution into institutional and high-moisture-use settings.

The established formulation uses nystatin at 100,000 units per gram with talc as the principal inactive ingredient. A competing product can pursue an ANDA where it matches the reference product’s dosage form, strength, route, and active-ingredient performance. A more differentiated product may require a 505(b)(2) pathway if it changes the excipient system, delivery device, or clinical performance profile in a material way.[1-3]

What is nystatin topical powder used for?

Nystatin topical powder is used for cutaneous and mucocutaneous infections caused by Candida species. Typical applications include candidal diaper dermatitis, intertrigo, infection in skin folds, and candidiasis in areas exposed to heat and moisture.

The powder format is commercially useful where creams or ointments are undesirable. It can reduce occlusion, limit direct skin contact during application, and help manage moisture in skin folds. Product labeling generally directs application two or three times daily, depending on the indication and product label.[1]

Product characteristic	Established market position
Active ingredient	Nystatin
Typical strength	100,000 units/g
Dosage form	Topical powder
Route	Cutaneous
Main indication	Cutaneous candidiasis
Typical excipient	Talc
Regulatory category	Prescription drug in the United States
Primary competitors	Generic nystatin powders, nystatin creams, ointments, and combination products
Main commercial differentiator	Moisture management and delivery convenience

What excipients are used in nystatin topical powder?

The reference formulation relies on a powder base that allows nystatin to disperse across the skin. Talc is the most established excipient in U.S. nystatin topical powder labeling.[1,4]

Talc

Talc provides bulk, flow, spreadability, and a dry sensory profile. Its advantages are low cost, established pharmaceutical use, and compatibility with dry powder manufacturing. Its disadvantages include dust generation, inhalation concerns, potential user aversion, and heightened scrutiny of mineral-source controls.

A commercial talc strategy should include:

• Pharmaceutical-grade source qualification.
• Asbestos testing and supplier controls.
• Particle-size distribution limits.
• Limits on respirable dust.
• Microbial and heavy-metal specifications.
• Controls for flow, density, and electrostatic behavior.
• Packaging designed to minimize airborne powder.

FDA has recognized that talc quality depends on mineral source and testing controls. The risk profile is different for topical use than for inhalation, but powder aerosolization remains a product-design issue.[5]

Corn starch and other starches

Corn starch can improve moisture absorption and reduce reliance on talc. It is inexpensive and familiar in topical powders. The main risks are microbial control, moisture sensitivity, clumping, variable flow, and potential concerns in compromised skin.

Starch-based formulations are most attractive where the product claim emphasizes moisture absorption rather than a talc-free positioning alone. The formulation must demonstrate adequate nystatin potency, content uniformity, microbial quality, and physical stability throughout shelf life.

Zinc oxide

Zinc oxide can provide a protective barrier and may appeal to diaper-care or irritated-skin segments. It increases formulation complexity and may reduce powder flow at higher concentrations. Zinc oxide also changes the sensory profile and can make the product more difficult to remove from skin and textiles.

A nystatin-zinc oxide powder could target candidal diaper dermatitis, but it may no longer be a simple substitute for an established nystatin-only powder. The sponsor would need to assess whether the combination creates a new regulatory product, a new clinical claim, or a formulation that requires additional safety data.

Colloidal silicon dioxide

Colloidal silicon dioxide can improve flow and reduce caking at low concentrations. It is generally a processing aid rather than the principal powder base. Excessive use can increase dustiness and create a less acceptable skin feel.

Kaolin and mineral alternatives

Kaolin and other mineral powders may improve absorbency and provide talc-free positioning. They can also increase density, alter spreadability, and create a visible residue. These materials require tight control of elemental impurities and mineral composition.

Cyclodextrins and advanced carriers

Cyclodextrins, porous silica, lipid carriers, and polymeric microparticles could improve dispersion or reduce dust. Their commercial value depends on whether they produce a measurable benefit, such as improved dose uniformity, lower airborne particulate generation, better adhesion, or longer residence on moist skin.

These systems are more likely to support a 505(b)(2) product or a formulation patent than a conventional ANDA. They also increase development cost and may complicate bioequivalence or comparative performance testing.

Which excipient strategy is commercially strongest?

The most practical strategy is a talc-free or reduced-talc powder with validated moisture management and improved packaging. A sponsor should avoid changing several variables at once.

Strategy	Commercial benefit	Main development risk	Likely regulatory path
Talc-only formulation	Lowest cost and highest familiarity	Limited differentiation	ANDA
Reduced-talc formulation	Lower mineral exposure and improved positioning	Flow and uniformity problems	ANDA or 505(b)(2), depending on formulation
Starch-based powder	Strong moisture-absorption positioning	Microbial growth and caking	ANDA or 505(b)(2)
Nystatin plus zinc oxide	Barrier and diaper-care positioning	New clinical and labeling complexity	505(b)(2) or separate combination pathway
Low-dust powder	Better caregiver handling	Requires particle-engineering validation	ANDA if sameness is maintained
Metered-dose powder device	Dose control and institutional usability	Device-drug combination requirements	505(b)(2) or combination-product pathway
Adherent or film-forming powder	Longer residence time	Skin tolerability and removal issues	505(b)(2)
Single-use sachets	Hygiene and institutional convenience	Higher packaging cost	ANDA if formulation is unchanged

What patents protect nystatin topical powder?

Nystatin is an old polyene antifungal. The original discovery and early composition patents are long expired. Current market protection is therefore more likely to arise from formulation, packaging, delivery-device, manufacturing, or method-of-use patents than from the nystatin molecule itself.

For a conventional U.S. nystatin topical powder, the practical patent position is generally weak because:

1. Nystatin is an established active ingredient.
2. Talc-based topical powders are conventional dosage forms.
3. The indication is well established.
4. Generic topical products have been marketed for years.
5. Any remaining protection is more likely to be product-specific than molecule-specific.

The relevant patent-screening categories are:

Patent category	Relevance to nystatin powder
Nystatin composition patents	Little current relevance because of age
Salt or polymorph patents	Generally limited for nystatin topical powder
Powder formulation patents	Potentially relevant for novel excipient systems
Low-dust delivery patents	Potential opportunity
Moisture-control patents	Potential opportunity if tied to a specific composition
Packaging patents	Relevant for unit-dose or metered delivery
Method-of-use patents	Possible for narrow populations or treatment regimens
Manufacturing patents	Possible for particle engineering or content uniformity
Device patents	Relevant to metered or spray powder systems

What is the Orange Book status of nystatin topical powder?

Nystatin topical powder products may appear in FDA product databases through approved NDAs or ANDAs, but the commercial importance of Orange Book protection is limited when no unexpired, product-blocking patent is listed.

The Orange Book records patents and exclusivity associated with approved drug products. It does not create patent rights. A listed patent can be challenged through a Paragraph IV certification, but an applicant must first identify the reference product and applicable listed patents.[2]

For nystatin topical powder, the likely regulatory conclusions are:

• No meaningful new-chemical-entity exclusivity remains.
• Any pediatric or other statutory exclusivity must be checked product by product.
• Patent listings, if present, must be reviewed against the exact reference product.
• An ANDA applicant may be able to certify Paragraph III, Paragraph IV, or that no relevant patent information is listed, depending on the Orange Book record.[2]

When does nystatin topical powder lose exclusivity?

Nystatin’s original active-ingredient exclusivity expired decades ago. The commercial market is therefore already exposed to generic competition. Any remaining exclusivity would arise from a specific approved product, patent, formulation, device, or narrow method of use rather than from nystatin itself.

Exclusivity type	Position for nystatin topical powder
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not generally applicable
New formulation exclusivity	Product-specific
Pediatric exclusivity	Product-specific
Patent exclusivity	Depends on listed patents
Reference-product exclusivity	Must be verified in FDA databases

Are there Paragraph IV challenges for nystatin topical powder?

Paragraph IV litigation is less commercially significant for an old, simple topical powder than for a newly approved drug with active formulation patents. A Paragraph IV challenge could still arise if a reference product has an unexpired listed patent covering a delivery device, excipient combination, manufacturing process, or use.

The practical competitive question is not whether nystatin itself can be challenged. It is whether the proposed generic infringes any live patent listed against the relevant reference product.

A generic applicant should evaluate:

• The exact reference-listed drug.
• All Orange Book patent listings.
• Patent expiration and pediatric-extension dates.
• The scope of formulation claims.
• Whether the proposed product uses the same inactive ingredients.
• Whether the product relies on a different delivery mechanism.
• Whether a Paragraph IV certification creates 30-month litigation risk under the Hatch-Waxman framework.[2,6]

What regulatory pathway applies to a new nystatin topical powder?

ANDA pathway

An ANDA is the most efficient path for a powder that matches the reference product in strength, dosage form, route, active ingredient, and essential performance characteristics. The sponsor must address:

• Pharmaceutical equivalence.
• Assay and content uniformity.
• Particle-size distribution.
• Powder flow and density.
• Microbial limits.
• Stability.
• Container-closure performance.
• Comparative in vitro or other required performance testing.
• Labeling consistency.

For a topical powder, sameness of inactive ingredients may be more difficult than for a simple tablet. A different excipient system can affect adhesion, dose delivery, spreadability, moisture uptake, and clinical performance.

505(b)(2) pathway

A 505(b)(2) application may be more suitable for:

• A talc-free formulation with a distinct delivery profile.
• A nystatin-zinc oxide combination.
• A metered-dose powder.
• A low-dust inhalation-controlled topical device.
• A formulation with a new dosing frequency.
• A product with a new indication or patient population.
• A powder with a novel residence-time or moisture-barrier mechanism.

The 505(b)(2) pathway can provide a more defensible commercial position, but it generally requires more development work and may expose the product to new clinical, safety, and patent questions.[3]

What formulation patents could protect a new product?

The strongest patent opportunities are narrow and technical. Broad claims to “nystatin in a topical powder” are vulnerable to prior art.

Potential claim areas include:

1. A defined particle-size distribution that reduces airborne dust while preserving skin coverage.
2. A specific ratio of nystatin to starch, silica, zinc oxide, or another carrier.
3. A moisture-triggered adhesion system.
4. A unit-dose package that prevents contamination and controls application.
5. A metered-dose dispensing mechanism.
6. A powder with defined water activity and microbial stability.
7. A manufacturing process that improves nystatin uniformity.
8. A formulation that maintains potency under high humidity.
9. A composition that reduces residue on clothing or bedding.
10. A combination formulation for a defined candidiasis population.

Patent strength will depend on unexpected performance data. Useful evidence includes lower dust, better dose recovery, improved moisture absorption, improved retention on skin, reduced caking, longer stability, or superior user handling.

What manufacturing and intellectual-property barriers exist?

Nystatin is a fermentation-derived active ingredient. Manufacturing barriers include fermentation consistency, potency assay variability, impurity control, particle engineering, and uniform blending into a low-dose powder base.

Because nystatin is measured in biological units rather than only mass, assay methodology and batch-to-batch potency control are central. A powder manufacturer must demonstrate uniform distribution of the active ingredient across the container and over the shelf life.

The main defensible manufacturing assets may include:

• Supplier qualification for pharmaceutical-grade nystatin.
• Controlled milling or classification.
• Anti-segregation blending.
• Humidity-controlled processing.
• Low-dust filling.
• Specialized unit-dose packaging.
• Validated microbial-control procedures.

These assets can support trade-secret protection even where patent protection is limited.

How does nystatin topical powder compare with competing dosage forms?

Dosage form	Strength	Limitation	Commercial position
Powder	Moisture control and non-occlusive use	Dust and application variability	Strong in folds and diaper-care settings
Cream	Easy spreading and broad consumer familiarity	More occlusive and less suitable for wet areas	Major generic competitor
Ointment	Barrier effect and retention	Greasy, occlusive, difficult to remove	Useful for fissured or irritated skin
Lotion	Spreadability over larger areas	Less moisture absorption	Niche
Combination cream	Addresses inflammation or mixed symptoms	More safety and labeling complexity	Higher differentiation, higher regulatory risk

A powder product should not compete only on price. Creams and ointments have broader consumer familiarity. The powder’s value proposition must focus on moisture control, reduced mess, ease of use in skin folds, and institutional handling.

What licensing opportunities exist for nystatin topical powder?

Licensing opportunities are more likely to involve technology than the nystatin molecule. Potential targets include:

• Low-dust powder platforms.
• Metered powder dispensers.
• Moisture-activated excipient systems.
• Unit-dose packaging.
• Barrier-forming mineral systems.
• Contract manufacturing with validated topical-powder capability.
• Regional distribution rights for hospital and long-term-care channels.

A licensee should avoid paying a premium for basic nystatin rights. Value is more defensible where the agreement includes issued patents, validated manufacturing know-how, regulatory data, and commercial access.

What generic launch scenarios exist?

Low-cost ANDA launch

A conventional talc-based generic can enter through price competition. This approach has the lowest development cost but limited differentiation and high vulnerability to market commoditization.

Talc-free launch

A talc-free product can target pharmacies, caregivers, and institutions that prefer alternative mineral systems. Commercial success depends on proving equivalent performance and maintaining acceptable powder flow.

Premium low-dust launch

A low-dust product can target pediatric caregivers, home health, hospitals, and long-term-care facilities. Packaging and dispensing controls are central to the value proposition.

Combination or barrier-protection launch

A nystatin product combined with zinc oxide or another protective excipient can target diaper dermatitis and irritated skin. This strategy offers more differentiation but creates greater regulatory and clinical complexity.

Geographic expansion

The United States, European Union, Canada, Latin America, and Asia-Pacific have different rules for prescription status, excipient acceptance, talc controls, and labeling. A global product should use modular packaging and region-specific regulatory files. The active ingredient is widely recognized, but local registration requirements for topical powders and excipients still apply.

What revenue exposure does nystatin topical powder have?

Nystatin topical powder is a mature, low-cost generic segment. Public company filings generally do not report revenue for this product separately. Revenue exposure is therefore determined by volume, channel access, supply reliability, and price rather than by exclusivity.

The highest-value commercial channels are likely to be:

• Institutional purchasing.
• Hospital discharge prescriptions.
• Long-term-care facilities.
• Pediatric and dermatology practices.
• Retail pharmacy generic dispensing.
• Government and public-health tenders.
• Private-label or regional branded generics.

A differentiated product can support higher net pricing, but the market ceiling is constrained by inexpensive nystatin creams, ointments, and established generic powders.

How strong is the patent estate for nystatin topical powder?

The patent estate is weak for conventional nystatin powder and potentially moderate for a genuinely differentiated delivery platform.

Asset type	Relative strength
Nystatin molecule	Very weak or expired
Conventional talc powder	Weak
Standard starch powder	Weak to moderate, depending on claims
Low-dust particle-engineered powder	Moderate
Metered dispensing system	Moderate to strong if technically novel
Moisture-triggered adhesion system	Moderate
Novel combination with zinc oxide	Moderate, but regulatory scope matters
Manufacturing process	Moderate, often better protected as know-how
Packaging and unit-dose system	Moderate

Key Takeaways

• Nystatin topical powder is a mature prescription antifungal product with little remaining molecule-level exclusivity.
• Talc is the established excipient, but talc-free, reduced-talc, starch-based, and low-dust systems offer clearer commercial differentiation.
• The strongest product concepts address moisture control, dust reduction, dose consistency, packaging hygiene, or skin retention.
• A conventional formulation is most compatible with an ANDA.
• A novel delivery system, combination product, or new clinical use may require a 505(b)(2) application.
• Paragraph IV risk is product-specific and depends on current Orange Book listings, not on nystatin’s historical patents.
• Formulation and device patents must rely on defined technical features and comparative performance data.
• Commercial value is concentrated in institutional channels, pediatric care, long-term care, and regional generic markets.
• The best licensing targets are delivery technology, manufacturing know-how, and market access rather than rights to nystatin itself.

FAQs

Is nystatin topical powder available over the counter?

In the United States, nystatin topical powder is generally marketed as a prescription product. OTC status depends on jurisdiction and the specific product authorization.

Can talc be replaced with corn starch in nystatin powder?

Yes, but the replacement affects flow, caking, microbial control, moisture uptake, and performance. The regulatory burden depends on whether the product remains pharmaceutically equivalent to the reference product.

Does nystatin topical powder have biosimilar competition?

No. Nystatin is a small-molecule antifungal, not a biologic. Biosimilar rules do not apply. Competition occurs through generic and alternative dosage-form pathways.

Can zinc oxide and nystatin be marketed as one topical powder?

Potentially, but the combination may require a distinct regulatory strategy. The sponsor must establish the legal basis for the combination, labeling, stability, safety, and clinical or comparative performance.

What is the best patent strategy for a new nystatin powder?

The strongest strategy is usually a focused portfolio covering low-dust particle engineering, moisture-triggered adhesion, metered dispensing, unit-dose packaging, or a defined excipient ratio supported by comparative data.

References

1. DailyMed. (n.d.). Nystatin topical powder prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2020). Applications covered by section 505(b)(2). https://www.fda.gov/drugs

4. United States Pharmacopeia. (2024). Nystatin and nystatin topical powder monographs. United States Pharmacopeial Convention. https://www.usp.org/

5. U.S. Food and Drug Administration. (2020). Testing methods for asbestos in talc-containing cosmetic products. https://www.fda.gov/cosmetics

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. Pub. L. No. 98-417.